Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103


Responses to "Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study": authors' reply.

Henrotin Y, Donneau AF, de Vlam K, Wittoek R, Luyten F.

Arthritis Res Ther. 2020 Feb 11;22(1):23. doi: 10.1186/s13075-020-2109-2. No abstract available.


Multi-segment spine and hip kinematics in asymptomatic individuals during standardized return from forward bending versus functional box lifting.

Seerden SFL, Dankaerts W, Swinnen TW, Westhovens R, de Vlam K, Vanwanseele B.

J Electromyogr Kinesiol. 2019 Dec;49:102352. doi: 10.1016/j.jelekin.2019.102352. Epub 2019 Aug 22.


Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study.

Henrotin Y, Malaise M, Wittoek R, de Vlam K, Brasseur JP, Luyten FP, Jiangang Q, Van den Berghe M, Uhoda R, Bentin J, De Vroey T, Erpicum L, Donneau AF, Dierckxsens Y.

Arthritis Res Ther. 2019 Jul 27;21(1):179. doi: 10.1186/s13075-019-1960-5.


Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.

JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. Erratum in: JAMA. 2020 Feb 4;323(5):480.


Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H.

Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28.


Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments.

Vandendorpe AS, de Vlam K, Lories R.

RMD Open. 2019 Jan 22;5(1):e000779. doi: 10.1136/rmdopen-2018-000779. eCollection 2019.


Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.


Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.


The need for comparative data in spondyloarthritis.

Choy E, Baraliakos X, Behrens F, D'Angelo S, de Vlam K, Kirkham BW, Østergaard M, Schett GA, Rissler M, Chaouche-Teyara K, Perella C.

Arthritis Res Ther. 2019 Jan 22;21(1):32. doi: 10.1186/s13075-019-1812-3.


Widespread pain in axial spondyloarthritis: clinical importance and gender differences.

Swinnen TW, Westhovens R, Dankaerts W, de Vlam K.

Arthritis Res Ther. 2018 Jul 27;20(1):156. doi: 10.1186/s13075-018-1626-8.


Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study.

de Vlam K, Merola JF, Birt JA, Sandoval DM, Lobosco S, Moon R, Milligan G, Boehncke WH.

Rheumatol Ther. 2018 Dec;5(2):423-436. doi: 10.1007/s40744-018-0120-8. Epub 2018 Jul 6.


Spondyloarthritis in the Democratic Republic of the Congo: a prospective hospital-based study.

Lebughe P, de Vlam K, Westhovens R, Mbuyi-Muamba JM, Malemba JJ.

BMJ Open. 2018 May 9;8(5):e020329. doi: 10.1136/bmjopen-2017-020329.


Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.

Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K.

J Rheumatol. 2018 Feb;45(2):153-157. doi: 10.3899/jrheum.170222. No abstract available.


Activity Limitations in Patients with Axial Spondyloarthritis: A Role for Fear of Movement and (Re)injury Beliefs.

Swinnen TW, Vlaeyen JWS, Dankaerts W, Westhovens R, de Vlam K.

J Rheumatol. 2018 Mar;45(3):357-366. doi: 10.3899/jrheum.170318. Epub 2017 Nov 15.


Bone Disease in Axial Spondyloarthritis.

Van Mechelen M, Gulino GR, de Vlam K, Lories R.

Calcif Tissue Int. 2018 May;102(5):547-558. doi: 10.1007/s00223-017-0356-2. Epub 2017 Oct 31. Review.


A Rare Cause of Weight Loss in an 80y Old Ankylosing Spondylitis Patient.

Westhovens I, Thielens I, De Vlam K, Westhovens R, Delva T.

J Clin Rheumatol. 2017 Apr;23(3):170-171. doi: 10.1097/RHU.0000000000000505. No abstract available.


Diverging illness perceptions between physicians about patients with systemic lupus erythematosus and systemic sclerosis: a vignette-based study.

Arat S, Moons P, Vandenberghe J, Lenaerts JL, de Vlam K, Westhovens R.

Rheumatol Int. 2017 Jun;37(6):915-922. doi: 10.1007/s00296-017-3667-8. Epub 2017 Feb 28.


Accelerometry-Based Activity Recognition and Assessment in Rheumatic and Musculoskeletal Diseases.

Billiet L, Swinnen TW, Westhovens R, de Vlam K, Van Huffel S.

Sensors (Basel). 2016 Dec 16;16(12). pii: E2151. doi: 10.3390/s16122151.


Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study.

Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1606-1611. doi: 10.1002/acr.23172. Epub 2017 Sep 6.


A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement.

Geuens J, Swinnen TW, Westhovens R, de Vlam K, Geurts L, Vanden Abeele V.

JMIR Mhealth Uhealth. 2016 Oct 13;4(4):e118.


EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.


Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort.

Haque N, Lories RJ, de Vlam K.

RMD Open. 2016 Aug 17;2(2):e000293. doi: 10.1136/rmdopen-2016-000293. eCollection 2016.


Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanercept.

de Vlam K, Bruhwyler J, Boone C; and the PROVE Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1094-1097. Epub 2016 Aug 31.


Limited association between scalp psoriasis and psoriatic arthritis severity and treatment response.

de Vlam K, Mallbris L, Szumski A, Jones H.

Clin Exp Rheumatol. 2017 Jan-Feb;35(1):141-144. Epub 2016 Aug 31.


Instrumented BASFI (iBASFI) Shows Promising Reliability and Validity in the Assessment of Activity Limitations in Axial Spondyloarthritis.

Swinnen TW, Milosevic M, Van Huffel S, Dankaerts W, Westhovens R, de Vlam K.

J Rheumatol. 2016 Aug;43(8):1532-40. doi: 10.3899/jrheum.150439. Epub 2016 Jun 15. Erratum in: J Rheumatol. 2016 Aug;43(8):1618.


Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries.

Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A, Balint PV, Niedermayer DS, Cañete JD, Helliwell P, Kalyoncu U, Kiltz U, Otsa K, Veale DJ, de Vlam K, Scrivo R, Stamm T, Kvien TK, Gossec L.

Joint Bone Spine. 2016 Jul;83(4):439-43. doi: 10.1016/j.jbspin.2015.07.017. Epub 2016 Apr 4.


Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25.


Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept.

Detrez I, Brouwers E, Peeters M, Geukens N, de Vlam K, Gils A.

J Immunol. 2016 Mar 15;196(6):2879-84. doi: 10.4049/jimmunol.1502195. Epub 2016 Feb 3.


CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis.

Siebuhr AS, Bay-Jensen AC, Karsdal MA, Lories RJ, de Vlam K.

Biomark Med. 2016;10(2):197-208. doi: 10.2217/bmm.15.119. Epub 2016 Jan 14.


Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study.

Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L.

Joint Bone Spine. 2016 May;83(3):335-40. doi: 10.1016/j.jbspin.2015.06.018. Epub 2015 Dec 8.


Comorbidities Associated with Psoriatic Arthritis Compared with Non-psoriatic Spondyloarthritis: A Cross-sectional Study.

Haque N, Lories RJ, de Vlam K.

J Rheumatol. 2016 Feb;43(2):376-82. doi: 10.3899/jrheum.141359. Epub 2015 Dec 15.


Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study).

de Vlam K, Boone C, The Prove Study Group A.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):624-31. Epub 2015 Jul 23.


Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.

Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, Tarallo M.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11-9. Epub 2014 Dec 22.


Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.

Lories RJ, de Vlam K.

Expert Opin Biol Ther. 2014 Dec;14(12):1825-36. doi: 10.1517/14712598.2014.967211. Epub 2014 Nov 4. Review.


Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.

Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, Luime JJ, Elkayam O, Neerinckx B, Urbancek S, de Vlam K, Ritchlin CT; GRAPPA Enthesitis Working Group.

J Rheumatol. 2014 Nov;41(11):2290-4. doi: 10.3899/jrheum.140878. Review.


A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK; EULAR PsAID Taskforce.

Ann Rheum Dis. 2014 Jun;73(6):1012-9. doi: 10.1136/annrheumdis-2014-205207.


Physical activity assessment in patients with axial spondyloarthritis compared to healthy controls: a technology-based approach.

Swinnen TW, Scheers T, Lefevre J, Dankaerts W, Westhovens R, de Vlam K.

PLoS One. 2014 Feb 28;9(2):e85309. doi: 10.1371/journal.pone.0085309. eCollection 2014.


Current concepts in psoriatic arthritis: pathogenesis and management.

de Vlam K, Gottlieb AB, Mease PJ.

Acta Derm Venereol. 2014 Nov;94(6):627-34. doi: 10.2340/00015555-1833. Review.


Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR).

Westhovens I, Lories RJ, Westhovens R, Verschueren P, de Vlam K.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):71-6. Epub 2013 Dec 2.


Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.

Ann Rheum Dis. 2014 Oct;73(10):1819-25. doi: 10.1136/annrheumdis-2013-203425. Epub 2013 Jul 14.


Investigating the genetic association between ERAP1 and spondyloarthritis.

Kadi A, Izac B, Said-Nahal R, Leboime A, Van Praet L, de Vlam K, Elewaut D, Chiocchia G, Breban M.

Ann Rheum Dis. 2013 Apr;72(4):608-13. doi: 10.1136/annrheumdis-2012-201783. Epub 2012 Aug 15.


Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.

Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627.


The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).

Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA.

Ann Rheum Dis. 2013 Jun;72(6):986-91. doi: 10.1136/annrheumdis-2012-201341. Epub 2012 Jul 13.


Is psoriatic arthritis a result of abnormalities in acquired or innate immunity?

Lories RJ, de Vlam K.

Curr Rheumatol Rep. 2012 Aug;14(4):375-82. doi: 10.1007/s11926-012-0257-3. Review.


European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P; European League Against Rheumatism.

Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. Epub 2011 Sep 27.


The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):672-80. Epub 2011 Aug 31.


Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases.

Op De Beéck K, Maes L, Van den Bergh K, Derua R, Waelkens E, Van Steen K, Vermeersch P, Westhovens R, De Vlam K, Verschueren P, Hooijkaas H, Blockmans D, Bossuyt X.

Arthritis Rheum. 2012 Jan;64(1):213-21. doi: 10.1002/art.33327.


The kaleidoscopic presentation of the spondyloarthritis concept in a female patient.

De Langhe E, Lories R, Maenaut K, De Vlam K.

Joint Bone Spine. 2011 Dec;78(6):638-40. doi: 10.1016/j.jbspin.2011.04.015. Epub 2011 Jun 23.


Systematic candidate gene investigations in the SPA2 locus (9q32) show an association between TNFSF8 and susceptibility to spondylarthritis.

Zinovieva E, Kadi A, Letourneur F, Cagnard N, Izac B, Vigier A, Said-Nahal R, Elewaut D, de Vlam K, Pimentel-Santos F, Chiocchia G, Breban M.

Arthritis Rheum. 2011 Jul;63(7):1853-9. doi: 10.1002/art.30377.


Destructive dural ectasia of dorsal and lumbar spine with cauda equina syndrome in a patient with ankylosing spondylitis.

Van Hoydonck M, de Vlam K, Westhovens R, Luyten FP, Lories RJ.

Open Rheumatol J. 2010 Aug 26;4:31-4. doi: 10.2174/1874312901004010031.

Supplemental Content

Loading ...
Support Center